Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Postpartum Hemorrhage | 7 | 2023 | 69 | 3.380 |
Why?
|
| Contraceptive Agents, Female | 8 | 2024 | 47 | 2.550 |
Why?
|
| Intrauterine Devices, Copper | 6 | 2024 | 20 | 2.220 |
Why?
|
| Medroxyprogesterone Acetate | 9 | 2024 | 44 | 1.980 |
Why?
|
| Labor Stage, Second | 2 | 2024 | 13 | 1.630 |
Why?
|
| Levonorgestrel | 5 | 2024 | 17 | 1.380 |
Why?
|
| Uterine Balloon Tamponade | 2 | 2020 | 8 | 1.360 |
Why?
|
| Cesarean Section | 2 | 2020 | 86 | 1.280 |
Why?
|
| Norethindrone | 4 | 2024 | 26 | 1.240 |
Why?
|
| Depression | 2 | 2021 | 117 | 1.220 |
Why?
|
| Pregnancy | 18 | 2024 | 1815 | 1.200 |
Why?
|
| Female | 31 | 2024 | 8751 | 1.160 |
Why?
|
| Dystocia | 3 | 2024 | 10 | 1.140 |
Why?
|
| Labor Stage, First | 1 | 2024 | 8 | 0.940 |
Why?
|
| Humans | 33 | 2024 | 14077 | 0.930 |
Why?
|
| Oxytocics | 2 | 2023 | 52 | 0.920 |
Why?
|
| HIV Infections | 11 | 2024 | 4946 | 0.900 |
Why?
|
| Developing Countries | 2 | 2024 | 385 | 0.800 |
Why?
|
| Heart Rate, Fetal | 1 | 2020 | 19 | 0.710 |
Why?
|
| Contraception | 4 | 2024 | 90 | 0.630 |
Why?
|
| Progestins | 4 | 2024 | 14 | 0.620 |
Why?
|
| Dysmenorrhea | 1 | 2017 | 2 | 0.600 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2017 | 2 | 0.600 |
Why?
|
| Long-Acting Reversible Contraception | 1 | 2017 | 11 | 0.600 |
Why?
|
| Young Adult | 11 | 2024 | 2357 | 0.560 |
Why?
|
| South Africa | 16 | 2023 | 7312 | 0.520 |
Why?
|
| Pre-Eclampsia | 3 | 2023 | 56 | 0.500 |
Why?
|
| Adult | 12 | 2024 | 5664 | 0.500 |
Why?
|
| Anti-HIV Agents | 5 | 2022 | 1275 | 0.490 |
Why?
|
| Delivery, Obstetric | 2 | 2024 | 78 | 0.440 |
Why?
|
| Lopinavir | 4 | 2021 | 137 | 0.400 |
Why?
|
| Ritonavir | 4 | 2021 | 137 | 0.400 |
Why?
|
| Parturition | 2 | 2021 | 30 | 0.360 |
Why?
|
| Lamivudine | 3 | 2021 | 86 | 0.360 |
Why?
|
| Dietary Supplements | 3 | 2023 | 40 | 0.360 |
Why?
|
| Suction | 2 | 2020 | 10 | 0.350 |
Why?
|
| Research Design | 2 | 2021 | 123 | 0.310 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2024 | 7 | 0.300 |
Why?
|
| Testosterone | 2 | 2024 | 14 | 0.300 |
Why?
|
| Tanzania | 2 | 2024 | 84 | 0.280 |
Why?
|
| Oxytocin | 2 | 2023 | 24 | 0.280 |
Why?
|
| Breast Feeding | 2 | 2018 | 119 | 0.270 |
Why?
|
| Adolescent | 7 | 2024 | 2858 | 0.270 |
Why?
|
| Tranexamic Acid | 2 | 2023 | 13 | 0.260 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2021 | 467 | 0.250 |
Why?
|
| Midwifery | 1 | 2024 | 12 | 0.240 |
Why?
|
| Botswana | 1 | 2024 | 24 | 0.240 |
Why?
|
| Estradiol | 1 | 2024 | 18 | 0.230 |
Why?
|
| Acne Vulgaris | 1 | 2024 | 4 | 0.230 |
Why?
|
| Double-Blind Method | 3 | 2019 | 263 | 0.230 |
Why?
|
| Obstetric Labor Complications | 1 | 2024 | 25 | 0.230 |
Why?
|
| HIV-1 | 3 | 2022 | 1239 | 0.230 |
Why?
|
| Clinical Trials as Topic | 1 | 2023 | 112 | 0.220 |
Why?
|
| Patient Care Bundles | 1 | 2023 | 4 | 0.220 |
Why?
|
| Calcium | 2 | 2023 | 49 | 0.210 |
Why?
|
| Early Diagnosis | 1 | 2023 | 80 | 0.210 |
Why?
|
| Maternal Death | 1 | 2023 | 25 | 0.210 |
Why?
|
| Treatment Outcome | 3 | 2020 | 867 | 0.210 |
Why?
|
| Health Personnel | 2 | 2022 | 229 | 0.200 |
Why?
|
| Chorioamnionitis | 1 | 2022 | 10 | 0.200 |
Why?
|
| Sexual Behavior | 1 | 2024 | 313 | 0.200 |
Why?
|
| Labor, Obstetric | 1 | 2022 | 44 | 0.200 |
Why?
|
| London | 2 | 2018 | 8 | 0.190 |
Why?
|
| Postpartum Period | 1 | 2021 | 78 | 0.190 |
Why?
|
| Chemoprevention | 1 | 2021 | 33 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 186 | 0.180 |
Why?
|
| Occupational Exposure | 1 | 2021 | 35 | 0.180 |
Why?
|
| HIV Seropositivity | 1 | 2022 | 263 | 0.170 |
Why?
|
| Random Allocation | 1 | 2019 | 23 | 0.170 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 57 | 0.170 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2022 | 171 | 0.170 |
Why?
|
| Feasibility Studies | 1 | 2019 | 95 | 0.160 |
Why?
|
| HIV Protease Inhibitors | 1 | 2019 | 92 | 0.160 |
Why?
|
| Calcium Carbonate | 1 | 2017 | 3 | 0.150 |
Why?
|
| Pregnancy, Unplanned | 1 | 2017 | 19 | 0.150 |
Why?
|
| Preconception Care | 1 | 2017 | 11 | 0.150 |
Why?
|
| Mass Screening | 1 | 2019 | 242 | 0.150 |
Why?
|
| Patient Selection | 1 | 2017 | 40 | 0.150 |
Why?
|
| Prenatal Care | 1 | 2019 | 141 | 0.150 |
Why?
|
| Infant | 5 | 2022 | 2145 | 0.140 |
Why?
|
| Abortion, Legal | 1 | 2016 | 7 | 0.130 |
Why?
|
| Burkina Faso | 3 | 2021 | 29 | 0.130 |
Why?
|
| Contraception Behavior | 1 | 2016 | 54 | 0.130 |
Why?
|
| Risk Factors | 4 | 2022 | 1431 | 0.120 |
Why?
|
| Injections, Intramuscular | 2 | 2024 | 30 | 0.120 |
Why?
|
| Child | 4 | 2021 | 2180 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 237 | 0.110 |
Why?
|
| Nigeria | 2 | 2023 | 40 | 0.100 |
Why?
|
| Male | 5 | 2022 | 6489 | 0.100 |
Why?
|
| Kenya | 2 | 2023 | 173 | 0.100 |
Why?
|
| Drug Implants | 2 | 2024 | 21 | 0.090 |
Why?
|
| Zambia | 2 | 2021 | 112 | 0.080 |
Why?
|
| Uganda | 2 | 2021 | 194 | 0.080 |
Why?
|
| Argentina | 2 | 2019 | 11 | 0.080 |
Why?
|
| Zimbabwe | 2 | 2019 | 115 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 367 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 532 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2021 | 939 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 1377 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2022 | 1410 | 0.060 |
Why?
|
| Mothers | 2 | 2018 | 190 | 0.060 |
Why?
|
| Androgens | 1 | 2024 | 5 | 0.060 |
Why?
|
| Contraceptive Agents | 1 | 2023 | 27 | 0.060 |
Why?
|
| Network Meta-Analysis | 1 | 2023 | 8 | 0.060 |
Why?
|
| Risk | 1 | 2023 | 87 | 0.050 |
Why?
|
| Calcium, Dietary | 1 | 2023 | 25 | 0.050 |
Why?
|
| Gynecological Examination | 1 | 2022 | 1 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2023 | 312 | 0.050 |
Why?
|
| Pain | 1 | 2022 | 40 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 235 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2022 | 113 | 0.050 |
Why?
|
| Tenofovir | 1 | 2022 | 158 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2022 | 137 | 0.050 |
Why?
|
| Neuropsychological Tests | 1 | 2021 | 55 | 0.050 |
Why?
|
| Mutation | 1 | 2022 | 299 | 0.050 |
Why?
|
| Steroid 21-Hydroxylase | 1 | 2020 | 1 | 0.050 |
Why?
|
| Genotype | 1 | 2022 | 430 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 104 | 0.050 |
Why?
|
| Obesity | 1 | 2023 | 356 | 0.040 |
Why?
|
| Drug Resistance, Viral | 1 | 2022 | 268 | 0.040 |
Why?
|
| Incidence | 1 | 2022 | 655 | 0.040 |
Why?
|
| Child Development | 1 | 2021 | 89 | 0.040 |
Why?
|
| Gestational Age | 1 | 2019 | 78 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 1131 | 0.040 |
Why?
|
| Africa | 1 | 2019 | 360 | 0.040 |
Why?
|
| Lactation | 1 | 2018 | 12 | 0.040 |
Why?
|
| Sample Size | 1 | 2017 | 4 | 0.040 |
Why?
|
| Recurrence | 1 | 2017 | 27 | 0.040 |
Why?
|
| Global Health | 1 | 2019 | 183 | 0.040 |
Why?
|
| Patient Dropouts | 1 | 2017 | 18 | 0.040 |
Why?
|
| Disease Progression | 1 | 2018 | 154 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2017 | 77 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2019 | 654 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2016 | 2 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 4 | 0.030 |
Why?
|
| Back Pain | 1 | 2016 | 4 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 2016 | 7 | 0.030 |
Why?
|
| Pregnancy Rate | 1 | 2016 | 8 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2021 | 1675 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2019 | 468 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 503 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2016 | 62 | 0.030 |
Why?
|
| Viral Load | 1 | 2019 | 808 | 0.030 |
Why?
|
Singata-Madliki's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(143)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(3)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_